Scholarlink

<p>X-ray triggered local activation of prodrugs is promising for tumor radio-chemo-immunotherapy. However, the insufficient active drugs within tumors under prescribed X-ray doses lead to poor immunogenic effects. Here, we proposed to develop ClO<sup>−</sup>-responsive nanoprodrug (DOX/S-M) that could persistently release DOX in response to inflammation induced by single-dose X-ray irradiation, thereby maintaining high levels of active DOX in tumors. DOX/S-M, prepared by the self-assembly of DOX-S-mPEG<sub>2000</sub> and tumor-targeting amphiphilic polymers (DSPE-PEG-Folate), were stable in normal environments. After X-ray irradiation, DOX/S-M, which was accumulated at the tumor site in a targeted manner for 24&#xa0;h, underwent collapse and DOX release for 24&#xa0;h in the presence of a high concentration of ClO<sup>−</sup> produced by the infiltration and activation of inflammatory cells. Consequently, DOX/S-M induced systemical immune responses through activating strong immunogenic cell death (ICD) following X-ray irradiation, exhibiting significant inhibition of both primary and distant tumors. Meanwhile, DOX/S-M showed negligible toxicity to normal tissues. In a word, this work developed an X-ray stimuli prodrug activation strategy for tumor radio-chemo-immunotherapy that utilizes X-ray triggered inflammatory response in tumors for controlled and persistent chemotherapeutic drugs activation, providing valuable guidance for exploring clinical anti-cancer strategy with low toxicity and high therapeutic efficacy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-dose X-ray driven persistent activation of nanoprodrugs for radio-chemo-immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月18日

查看全文
  • Yi-Qun Wu,
  • Dan-Dan Wang,
  • Jia-Mi Li,
  • Jiao-Jiao Ma,
  • Wang Qian,
  • Li He,
  • Bo Wu,
  • Shi-Wen Huang,
  • Jun Feng,
  • Kai Deng,
  • Yong-Chang Wei

摘要

X-ray triggered local activation of prodrugs is promising for tumor radio-chemo-immunotherapy. However, the insufficient active drugs within tumors under prescribed X-ray doses lead to poor immunogenic effects. Here, we proposed to develop ClO−-responsive nanoprodrug (DOX/S-M) that could persistently release DOX in response to inflammation induced by single-dose X-ray irradiation, thereby maintaining high levels of active DOX in tumors. DOX/S-M, prepared by the self-assembly of DOX-S-mPEG2000 and tumor-targeting amphiphilic polymers (DSPE-PEG-Folate), were stable in normal environments. After X-ray irradiation, DOX/S-M, which was accumulated at the tumor site in a targeted manner for 24 h, underwent collapse and DOX release for 24 h in the presence of a high concentration of ClO− produced by the infiltration and activation of inflammatory cells. Consequently, DOX/S-M induced systemical immune responses through activating strong immunogenic cell death (ICD) following X-ray irradiation, exhibiting significant inhibition of both primary and distant tumors. Meanwhile, DOX/S-M showed negligible toxicity to normal tissues. In a word, this work developed an X-ray stimuli prodrug activation strategy for tumor radio-chemo-immunotherapy that utilizes X-ray triggered inflammatory response in tumors for controlled and persistent chemotherapeutic drugs activation, providing valuable guidance for exploring clinical anti-cancer strategy with low toxicity and high therapeutic efficacy.

Graphical abstract